Nomura Holdings
VKTX icon

Nomura Holdings’s Viking Therapeutics VKTX Stock Holding History

Nomura Holdings’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,000
Closed -$1.06M – 2146
2025
Q4 		$1.06M Buy
+30,000
New +$1.06M ﹤0.01% 1320
2024
Q4 		– Sell
-4,500
Closed -$285K – 2416
2024
Q3 		$285K Buy
+4,500
New +$264K ﹤0.01% 1350

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Nomura Holdings's VKTX Position: Q1 2026 in Review

Nomura Holdings sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 30,000 shares — an estimated $1.06M sold.

Nomura Holdings first reported a position in VKTX in Q4 2019 and held it in 5 quarters. The position peaked at $1.06M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Nomura Holdings reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nomura Holdings sold 30,000 Viking Therapeutics shares in Q1 2026, an estimated $1.06M.
  • Nomura Holdings first reported a position in Viking Therapeutics in Q4 2019 and held it in 5 quarters.
  • Nomura Holdings's Viking Therapeutics position peaked at $1.06M in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.